Back to mobile site

Rodman & Renshaw Reiterates Buy Rating on Bicycle Therapeutics (BCYC)

February 25, 2025 9:45 AM EST Send to a Friend
Rodman & Renshaw analyst Tony Butler reiterated a Buy rating and $33.00 price target on Bicycle Therapeutics (NASDAQ: BCYC)The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login